Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03092609 · ClinicalTrials.gov registry record · NA

Neuroplasticity in an Extended Amygdala Network as a Target Mechanism for Attention Bias Modification Outcome

A NA study of Anxiety, sponsored by Northern Michigan University.

Completed
Registry status
NA
Development phase
119
Enrollment target
1
Study location

NCT03092609: Completed NA study of Anxiety, sponsored by Northern Michigan University.

NCT03092609 is a NA study of Anxiety that has completed, run by Northern Michigan University. The registered enrollment target is 119 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03092609, a NA study of Anxiety, has completed, sponsored by Northern Michigan University.

COMPLETED
Registry status
NA
Development phase
119 participants
Enrollment target
1
Study location

Study Summary

Anxiety disorders are one of the most common psychological disorders. Underlying anxiety is an increased attentional bias to threat, which has been identified as a causal contributor in the development of anxiety. Given this causal relationship, attention bias modification was introduced as a treatment option where anxiety is reduced by training individuals to direct their attention away from threat and thereby decreasing anxiety. Over a decade of research using this approach, called attention bias modification (ABM), suggests that overall the approach is effective in reducing anxiety. Although ABM appears to be a very promising treatment option for anxiety, there are several factors limiting the effectiveness of ABM. These include the recognition of individual-level needs and a known underlying mechanism of action by which ABM is effective. Neuroimaging evidence suggests that attentional bias to visual threat is associated with a network of brain regions including the amygdala, anterior cingulate cortex, and visual cortex. In human participants, experience-dependent neuroplasticity is visible in voxel-based morphometry based measures of gray matter volume following training. Recently, voxel-based morphometry measures of gray matter volume have been linked to dendritic spine density-a known cellular mechanism for learning-related neuroplasticity. Thus, voxel-based morphometry measures are ideally suited to measure learning-related neuroplasticity following attention bias modification. In this proposal participants' level of attentional bias, anxiety, and gray matter volume will be measured before and after completing six weeks of attention bias modification training (N = 50) or attention control training (N= 50). The proposal aims to (1) establish that pre-treatment bias predicts variability in gray matter volume in the extended amygdala and anterior cingulate cortex, (2) assess the extent to which reduced extended amygdala and anterior cingulate cortex gray matter

Primary Outcome

Reaction time difference to congruent and incongruent trials in the dot-probe task, which measure heightened attentional bias to threat.

Conditions Studied

Interventions

  • BEHAVIORAL Attention Control
  • BEHAVIORAL Attention Bias Modification

Study Locations (1)

Michigan

  • Northern Michigan University - Marquette

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2017-12-15
Est. Completion 2020-03-14
Phase NA
Northern Michigan University

4 total trials

What the finished NCT03092609 record still lists

NCT03092609 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Attention Control is the first listed.

NCT03092609 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT03092609 about?

NCT03092609 is a clinical study titled "Neuroplasticity in an Extended Amygdala Network as a Target Mechanism for Attention Bias Modification Outcome". Anxiety disorders are one of the most common psychological disorders. Underlying anxiety is an increased attentional bias to threat, which has been identified as a causal contributor in the development of anxiety. Given this causal relationship, attention bias modification was introduced as a treatm...

What is the current status of trial NCT03092609?

This trial is currently completed. It is a NA study. The enrollment target is 119 participants. The study started on 2017-12-15. Estimated completion is 2020-03-14.

What conditions does trial NCT03092609 study?

This clinical trial studies the following conditions: Anxiety.

What interventions are being tested in trial NCT03092609?

The interventions under investigation include: Attention Control (BEHAVIORAL), Attention Bias Modification (BEHAVIORAL).

Who is sponsoring clinical trial NCT03092609?

This trial is sponsored by Northern Michigan University, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03092609 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03092609's enrollment target sits among peer trials

119 144th of 364 higher than 221 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04870762 · 119 participants · Phase 2

    Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

  • NCT05559853 · 119 participants

    Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

  • NCT06564389 · 119 participants · Phase 1

    FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

  • NCT06742801 · 119 participants · NA

    Onyx™ Liquid Embolic IDE Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03092609, the US trial registry maintained by the National Library of Medicine. NCT03092609 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.